

## Summary of the MAQC June-2-2005 Teleconference

## The MAQC Project: Calibrated RNA Samples, Reference Datasets, and QC Metrics/Thresholds for Microarray Quality Control

Meeting Date: June 2, 2005 (9 am PDT / 11 am CDT / 12 pm EDT / 16:00 GMT)

Meeting Place: Teleconference Summary Date: June 4, 2005

Author: Leming Shi, FDA/NCTR, +1-870-543-7387, leming.shi@fda.hhs.gov

- 1. **Brain RNA**: Mike Wilson updated the progress on the manufacturing of the brain RNA sample: Two hundred milligrams (200 mgs) have already been made and passed Ambion's QC, and the first large batch in the amount of about one gram will be available by the 2<sup>nd</sup> week of July. The MAQC main study will start by the end of July.
- 2. **Pilot Titration**: Rich Shippy and Shawn Baker briefed the MAQC group on the issues discussed during the May 26 teleconference among potential participants of the Pilot Titration study. Two RNA samples (Ambion brain RNA and Stratagene UHRR) and 11 mixtures have been distributed to eight sites (Affymetrix, Applied Biosystems, Agilent, Combimatrix, GE Healthcare, Genospectra, Illumina, and Stratagene) and microarray data collection will be completed by the end of June. Criteria for selecting titration points for the MAQC main study were discussed. The 99.5/0.5 and 0.5/99.5 mixtures will be run in six replicates following Shawn's suggestion. A Pilot Titration teleconference was held on June 3 (Friday), and a summary from Rich is attached.
- 3. **Sequence-based Cross-platform Mapping**: Damir Herman (NCBI), Scott Pine (CDER), Zoltan Szallasi (Harvard), and Leming Shi (NCTR), a small group from non-commercial organizations, were tasked with sequence-based cross-platform mapping. MTA's are being prepared in order to gain access to probe sequence information. A strategy for cross-platform mapping will be developed by close consultation with manufacturers.
- 4. **Terms on the Use of the MAQC Datasets**: They were reiterated by Leming Shi:
  - MAQC main study: Datasets from all participants will be made publicly accessible after publication(s).
  - MAQC pilot studies (Pilot I RNA Sample Selection and Pilot II Titration): The publication/public access of the pilot datasets is voluntary but encouraged, and should be under the MAQC umbrella.
- 5. **New Data Analysis Site**: The request from Damir Herman (NCBI) to access the MAQC pilot datasets to aid gene selection for validation and sequence-based mapping was discussed and approved.
- 6. **Other Issues**: (A) Each platform provider was encouraged to select the test sites as soon as possible so that they could join future teleconference discussions; (B) FDA/NCTR is working on a Web site to disseminate MAQC related information.

## The Next MAOC Teleconference:

Thursday, June 16, 2005 (9 am PDT / 11 am CDT / 12 pm EDT / 16:00 GMT). Jim Fuscoe (FDA/NCTR) will be moderating the discussions.